Treatment with ibandronate preserves bone in experimental tumour-induced bone loss

Journal of Bone and Joint Surgery - Series B

Volumn 82, Issue 1, 2000, Pages 126-130

  Kurth, A H A ^a,b   Kim, S Z ^a   Sedlmeyer, I ^a   Hovy, L ^b   Bauss, F ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE ATROPHY; BONE METASTASIS; BONE STRENGTH; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; WALKER CARCINOMA;

EID: 0033957609     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.82B1.9483     Document Type: Article

References (37)

1. Galasko CS. The role of the orthopaedic surgeon in the treatment of bone pain. Cancer Surv 1988;7:103-25.
2. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19:663-7.
3. Galasko CSB. Skeletal metastases. London: Butterworth and Co. Ltd, 1986:14-124.
4. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
5. Toma S, Venturino A, Sogno G, et al. Metastatic bone tumors: non-surgical treatment, outcome and survival. Clin Orthop 1993;295: 246-51.
6. Friedl W. Indication, management and results of surgical therapy for pathological fractures in patients with bone metastases. Eur J Surg Oncol 1990;16:380-96.
7. Schmidt RG. Management of extremity metastatic bone cancer. Curr Probl Cancer 1995;19:166-82.
8. Mundy GR. Mechanisms of bone metastasis. Cancer 1997;8 Suppl, 80:1546-56.
9. Jung A, Bornand J, Mermillod B, Edouard C, Meunier PJ. Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer Res 1984;44:3007-11.
10. Krempien B, Wingen F, Eichmann T, Müller M, Schmahl D. Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1, 1 bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256. Oncology 1988;45:41-6.
11. Ralston SH, Thiebaud D, Hermann Z, et al. Dose-response study of ihandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997;75:295-300.
12. Wingen F, Eichmann T, Manegold C, Krempien B. Effects of new bisphosphonic acids on tumor induced hone destruction in the rat. J Cancer Res Clin Oncol 1986;111:35-41.
13. Bauss F. Ibandronate in malignant bone diseases and osteoporosis-preclinical results. Onkologie 1997;20:204-8.
14. Pecherstorfer M, Herrmann Z, Body JJ, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996;14: 268-76.
15. Wüster C, Schöter KH, Thiebaud D, et al. Methylpenthylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Mineral 1993;22:77-85.
16. Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
17. McCloskey EV, MacLennan IC, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998;100:317-25.
18. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma (Myeloma Aredia Study Group). N Engl J Med 1996; 334:488-93.
19. Elomaa I, Blomqvist C. Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy. Acta Oncol 1995; 34:629-36.
20. Kurth AA, Wang C, Shea M, Hayes WC. An animal model for the evaluation of biomechanical and densitometric properties of tumor induced hone loss. Trans Combined 7th Conference of European Orthopaedic Research Society, Barcelona, 1997:17.
21. Orr W, Varani J, Ward PA. Characteristics of the chemotactic response of neoplastic cells to a factor derived from the fifth component of complement. Am J Pathol 1978;93:405-22.
22. Sedar-Obermeier M, Bauss F. Effects of the bisphosptionate BM 21.0955 on hypercalcemia and hypercalcuria induced by Walker carcinosarcoma 256 in TPTX rats. Calc Tissue Int 1995;53 (Suppl 1):70.
23. Burstein AH, Frankel VH. A standard test for laboratory animal bone. J Biomechanics 1971;4:155-8.
24. Bonnarens F, Einhorn TA. Production of a standard closed fracture in laboratory animal bone. J Orthop Res 1984;2:97-101.
25. Seibel MJ, Lambrinoudaki I, Zipf A. Biochemical markers of bone metabolism in metastatic bone disease. In: Diel IJ, Kaufmann M, Bastert G, eds. Metastatic bone disease: fundamental and clinical aspects. Berlin, etc: Springer Verlag, 1994.
26. Hipp JA, Springfield DS, Hayes WC. Predicting pathologic fracture risk in the management of metastatic bone defects. Clin Orthop 1995; 312:120-35.
27. Leal CA, Shea M, Patterson JD, Hayes WC. Alendronate prevents strength loss from osseous metastatic defects in a rat model. Trans Orthop Res Soc 1995;20:210.
28. 45Ca kinetics in the intact rat. Osteoporosis Int 1996;6:166-70.
29. Guaitani A, Sabatini M, Coccioli G, et al. An experimental rat model of local bone cancer invasion and its responsiveness to ethane-1-hydroxy-1, 1-bis(phosphonate). Cancer Res 1985;45:2206-9.
30. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995;55:3551-7.
31. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997;99:2509-17.
32. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralised bone extracellular matrices. Cancer Res 1997;57: 3890-4.
33. Nemoto R, Sato S, Nishijima Y, et al. Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice. J Urol 1990;144:770-4.
34. Mühlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6: 1003-11.
35. Grauer A, Heichel S, Knaus J, Ziegler R. Long term effects of ibandronate treatment in Paget's disease of bone. J Bone Miner Res 1996; 11:498.
36. Monier-Faugere MC, Friedler RM, Bauss F, Malluche HH. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993;8:1345-55.
37. Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisophosphonate for prevention and treatment of postmenopausal osteoporosis: a 1 year, randomised, double blind, placebo-controlled dose finding study. Bone 1996;19:527-33.